FDA New Molecular Entity Approvals Rebound In 2004; Lyrica Is Fitting Finale
Executive Summary
FDA's new molecular entity drug approval tally for 2004 represents a five-year high for the agency
You may also be interested in...
Pfizer Sales Force Is “Critical” To Five-Year Strategy, McKinnell Says
Pfizer sees no need for significant changes to its sales force model for at least the next three to five years, CEO Hank McKinnell said Jan. 19
Pfizer Sales Force Is “Critical” To Five-Year Strategy, McKinnell Says
Pfizer sees no need for significant changes to its sales force model for at least the next three to five years, CEO Hank McKinnell said Jan. 19
Pfizer Lyrica Launch Awaits Controlled Substance Scheduling
Pfizer's launch of Lyrica will be delayed while pregabalin undergoes controlled substance scheduling at the Drug Enforcement Administration